PMID: 6963499Jan 1, 1981Paper

Clinical studies with mismatched double-stranded RNA

Texas Reports on Biology and Medicine
D R StrayerP O Ts'o

Abstract

Mismatched inducer/activator therapy has demonstrated areas of definite clinical promise in its initial human trials. Indeed, the mismatched dsRNA may even prove more efficacious than conventional (exogenous) interferon therapy for several reasons including: (a) First, the potential for generating multiple species of interferons, thereby removing the possible necessity of targeting a specific type (or subtype) of interferon to a particular cell type, (b) Secondly, the known ability of the mismatched inducer to activate the intracellular mediators which are synthesized after cellular exposure to the various types of interferon, (c) Lastly, the recently demonstrated ability of the inducer/activator in combination with interferon to override acquired cellular resistance to interferon alone (13).

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.